N-acetylcysteine amide augments the therapeutic effect of neural stem cell-based antiglioma oncolytic virotherapy

Molecular Therapy

Volumn 21, Issue 11, 2013, Pages 2063-2073

  Kim, Chung Kwon ^a   Ahmed, Atique U ^a   Auffinger, Brenda ^a   Ulasov, Ilya V ^a   Tobias, Alex L ^a   Moon, Kyung Sub ^b   Lesniak, MacIej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Chonnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; N ACETYLCYSTEINE AMIDE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGLIOMA ONCOLYTIC VIROTHERAPY; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; GLIOMA; IN VITRO STUDY; MOUSE; NEURAL STEM CELL; NONHUMAN; ONCOLYSIS; ONCOLYTIC VIROTHERAPY; ORTHOTROPIC GLIOMA; PROGENY; SURVIVAL TIME; TUMOR CELL DESTRUCTION; TUMOR XENOGRAFT; VIRUS RELEASE; VIRUS REPLICATION;

ADENOVIRIDAE;

ACETYLCYSTEINE; ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; GLIOMA; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOPLASMS, EXPERIMENTAL; NEURAL STEM CELLS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887448601     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.179     Document Type: Article

References (40)

1. Kornblith, PK, Welch, WC and Bradley, MK (1993). The future of therapy for glioblastoma. Surg Neurol 39: 538-543.
2. Stupp, R, Mason, WP, van den Bent, MJ, Weller, M, Fisher, B, Taphoorn, MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
3. Krex, D, Klink, B, Hartmann, C, von Deimling, A, Pietsch, T, Simon, M et al.; German Glioma Network. (2007). Long-term survival with glioblastoma multiforme. Brain 130(Pt 10): 2596-2606.
4. Giese, A and Westphal, M (1996). Glioma invasion in the central nervous system. Neurosurgery 39: 235-50; discussion 250.
5. Nicholas, MK, Lukas, RV, Chmura, S, Yamini, B, Lesniak, M and Pytel, P (2011). Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges. Semin Oncol 38: 243-253.
6. Thumma, SR, Elaimy, AL, Daines, N, Mackay, AR, Lamoreaux, WT, Fairbanks, RK et al. (2012). Long-term survival after gamma knife radiosurgery in a case of recurrent glioblastoma multiforme: a case report and review of the literature. Case Rep Med 2012: 545492.
7. Aghi, M and Martuza, RL (2005). Oncolytic viral therapies-the clinical experience. Oncogene 24: 7802-7816.
8. Ulasov, IV, Zhu, ZB, Tyler, MA, Han, Y, Rivera, AA, Khramtsov, A et al. (2007). Survivindriven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther 18: 589-602.
9. Ulasov, IV, Tyler, MA, Zhu, ZB, Han, Y, He, TC and Lesniak, MS (2009). Oncolytic adenoviral vectors which employ the survivin promoter induce glioma oncolysis via a process of beclin-dependent autophagy. Int J Oncol 34: 729-742.
10. Ulasov, IV, Sonabend, AM, Nandi, S, Khramtsov, A, Han, Y and Lesniak, MS (2009). Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. Br J Cancer 100: 1154-1164.
11. Ahmed, AU, Thaci, B, Alexiades, NG, Han, Y, Qian, S, Liu, F et al. (2011). Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma. Mol Ther 19: 1714-1726.
12. Thaci, B, Ahmed, AU, Ulasov, IV, Tobias, AL, Han, Y, Aboody, KS et al. (2012). Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model. Cancer Gene Ther 19: 431-442.
13. Yoo, JY, Pradarelli, J, Haseley, A, Wojton, J, Kaka, A, Bratasz, A et al. (2012). Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV. Clin Cancer Res 18: 4931-4941.
14. Cheema, TA, Kanai, R, Kim, GW, Wakimoto, H, Passer, B, Rabkin, SD et al. (2011). Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin Cancer Res 17: 7383-7393.
15. Hockenbery, DM, Oltvai, ZN, Yin, XM, Milliman, CL and Korsmeyer, SJ (1993). Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75: 241-251.
16. Kongara, S and Karantza, V (2012). The interplay between autophagy and ROS in tumorigenesis. Front Oncol 2: 171.
17. Offen, D, Gilgun-Sherki, Y, Barhum, Y, Benhar, M, Grinberg, L, Reich, R et al. (2004). A low molecular weight copper chelator crosses the blood-brain barrier and attenuates experimental autoimmune encephalomyelitis. J Neurochem 89: 1241-1251.
18. Gong, X, Celsi, G, Carlsson, K, Norgren, S and Chen, M (2010). N-acetylcysteine amide protects renal proximal tubular epithelial cells against iohexol-induced apoptosis by blocking p38 MAPK and iNOS signaling. Am J Nephrol 31: 178-188.
19. Mart, V, Herrera, F, Garc-Santos, G, Antol, I, Rodriguez-Blanco, J and Rodriguez, C (2007). Signaling pathways involved in antioxidant control of glioma cell proliferation. Free Radic Biol Med 42: 1715-1722.
20. Stanziale, SF, Petrowsky, H, Adusumilli, PS, Ben-Porat, L, Gonen, M and Fong, Y (2004). Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: a potential target to increase anticancer activity. Clin Cancer Res 10: 3225-3232.
21. Ahmed, AU, Tyler, MA, Thaci, B, Alexiades, NG, Han, Y, Ulasov, IV et al. (2011). A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol Pharm 8: 1559-1572.
22. Fink, K, Duval, A, Martel, A, Soucy-Faulkner, A and Grandvaux, N (2008). Dual role of NOX2 in respiratory syncytial virus-and sendai virus-induced activation of NF-kappaB in airway epithelial cells. J Immunol 180: 6911-6922.
23. DeNicola, GM, Karreth, FA, Humpton, TJ, Gopinathan, A, Wei, C, Frese, K et al. (2011). Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475: 106-109.
24. Hu, S, Sheng, WS, Schachtele, SJ and Lokensgard, JR (2011). Reactive oxygen species drive herpes simplex virus (HSV)-1-induced proinflammatory cytokine production by murine microglia. J Neuroinflammation 8: 123.
25. McGuire, KA, Barlan, AU, Griffin, TM and Wiethoff, CM (2011). Adenovirus type 5 rupture of lysosomes leads to cathepsin B-dependent mitochondrial stress and production of reactive oxygen species. J Virol 85: 10806-10813.
26. Kim, J and Wong, PK (2009). Loss of ATM impairs proliferation of neural stem cells through oxidative stress-mediated p38 MAPK signaling. Stem Cells 27: 1987-1998.
27. Grinberg, L, Fibach, E, Amer, J and Atlas, D (2005). N-acetylcysteine amide, a novel cell-permeating thiol, restores cellular glutathione and protects human red blood cells from oxidative stress. Free Radic Biol Med 38: 136-145.
28. Zhang, X, Banerjee, A, Banks, WA and Ercal, N (2009). N-Acetylcysteine amide protects against methamphetamine-induced oxidative stress and neurotoxicity in immortalized human brain endothelial cells. Brain Res 1275: 87-95.
29. Stupp, R, Hegi, ME, Mason, WP, van den Bent, MJ, Taphoorn, MJ, Janzer, RC et al.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459-466.
30. Lorence, RM, Rood, PA and Kelley, KW (1988). Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-alpha and augmentation of its cytotoxicity. J Natl Cancer Inst 80: 1305-1312.
31. Pecora, AL, Rizvi, N, Cohen, GI, Meropol, NJ, Sterman, D, Marshall, JL et al. (2002). Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 20: 2251-2266.
32. Yang, WQ, Lun, X, Palmer, CA, Wilcox, ME, Muzik, H, Shi, ZQ et al. (2004). Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clin Cancer Res 10: 8561-8576.
33. Ahmed, AU, Rolle, CE, Tyler, MA, Han, Y, Sengupta, S, Wainwright, DA et al. (2010). Bone marrow mesenchymal stem cells loaded with an oncolytic adenovirus suppress the anti-adenoviral immune response in the cotton rat model. Mol Ther 18: 1846-1856.
34. Benhar, M, Dalyot, I, Engelberg, D and Levitzki, A (2001). Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol Cell Biol 21: 6913-6926.
35. Storz, P (2005). Reactive oxygen species in tumor progression. Front Biosci 10: 1881-1896.
36. Madhavan, L, Ourednik, V and Ourednik, J (2006). Increased "vigilance" of antioxidant mechanisms in neural stem cells potentiates their capability to resist oxidative stress. Stem Cells 24: 2110-2119.
37. Fisher, K (2006). Striking out at disseminated metastases: the systemic delivery of oncolytic viruses. Curr Opin Mol Ther 8: 301-313.
38. Glass, R, Synowitz, M, Kronenberg, G, Walzlein, JH, Markovic, DS, Wang, LP et al. (2005). Glioblastoma-induced attraction of endogenous neural precursor cells is associated with improved survival. J Neurosci 25: 2637-2646.
39. Pluchino, S, Zanotti, L, Rossi, B, Brambilla, E, Ottoboni, L, Salani, G et al. (2005). Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature 436: 266-271.
40. Ahmed, AU, Ulasov, IV, Mercer, RW and Lesniak, MS (2012). Maintaining and loading neural stem cells for delivery of oncolytic adenovirus to brain tumors. Methods Mol Biol 797: 97-109.